It sounds as though the FDA and Neuren have been at loggerheads over these endooints, where shareholders were given the impression this was a minor matter that would be cleared up by email.. That is not good.
It also emphasises how clinical trial timelines always extend for much longer than people expect.
And whilst it might be seen as good that there is now a date being mentioned, that date is months away and it is a date for a meeting, not necessarily for an agreement or moving forward.
- Forums
- ASX - By Stock
- Ann: Type C Meeting granted by FDA for Phelan-McDermid syndrome
NEU
neuren pharmaceuticals limited
Add to My Watchlist
10.2%
!
$13.82

It sounds as though the FDA and Neuren have been at loggerheads...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$13.82 |
Change
1.280(10.2%) |
Mkt cap ! $1.559B |
Open | High | Low | Value | Volume |
$12.96 | $13.84 | $12.91 | $3.666M | 274.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 354 | $13.80 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.84 | 1 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 500 | 13.270 |
1 | 150 | 13.260 |
5 | 680 | 13.250 |
6 | 7776 | 13.240 |
3 | 411 | 13.230 |
Price($) | Vol. | No. |
---|---|---|
13.310 | 1530 | 3 |
13.320 | 436 | 3 |
13.330 | 2176 | 5 |
13.340 | 592 | 3 |
13.350 | 1092 | 3 |
Last trade - 10.22am 26/06/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
PTX
PRESCIENT THERAPEUTICS LIMITED
James McDonnell, CEO
James McDonnell
CEO
Previous Video
Next Video
SPONSORED BY The Market Online